Trestolone (7-alpha-methyl-19-nortestosterone, MENT) is a synthetic androgen related to nandrolone. It was developed and tested in small trials as an implant for male contraception and androgen replacement, but it has never been approved, and we found no trestolone product in FDA's Drugs@FDA database.
Also known as: MENT, 7α-methyl-19-nortestosterone, trestolone acetate.
For trestolone, there is no approved product, so there are no label strengths. The human trials used implants under the skin or study injections, not products sold today.
Trestolone is not approved in the US. It is not one of the substances named in the federal Schedule III list (21 CFR 1308.13(f)); the DEA definition of an anabolic steroid is not limited to that list, and whether it covers trestolone is a legal question we cannot answer here. WADA names trestolone (MENT) on its Prohibited List as an anabolic steroid, banned in and out of competition.
In healthy men, MENT strongly suppressed the body's own testosterone, LH and FSH; with two or four implants, testosterone fell by 93% on average and recovered after the implants were removed (Noé 1999), and single injections also lowered testosterone and gonadotropins (Suvisaari 1997). In a contraception trial with a progestogen (Walton 2007), sperm counts fell quickly at first, but suppression was not kept up as MENT release from the implants dropped, 6 men noticed loss of libido, and HDL cholesterol fell.
Anti-doping researchers reported in 2026 that no doping sample had been reported positive for MENT in two decades, possibly because it is hard to measure, and identified new urine metabolites to detect it (Piper 2026).
After a single injection of a study suspension into muscle, MENT peaked about 1 to 2 hours later (Suvisaari 1997), but the summary gives no half-life, and that form is not one sold today. So we do not list a half-life or time to peak.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator